NCT04998669 2026-02-10
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
University of Miami
Phase 2 Recruiting
Clinical Trials
9 trialsNCT05464719 2026-01-12
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05249959 2026-01-05
FIL_COLUMN
Fondazione Italiana Linfomi - ETS
Phase 2 Recruiting
NCT05453396 2025-10-16
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
University of Washington
Phase 2 Recruiting
NCT05672251 2025-10-06
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT05296070 2025-09-30
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
University of Miami
Phase 2 Recruiting
NCT07197307 2025-09-29
CLEAR
Universität Münster
Phase 2 Not yet recruiting
NCT05190705 2025-05-23
Loncastuximab Tesirine in WM
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06918912 2025-04-09
LORELY
Istituto Clinico Humanitas
Phase 2 Recruiting